Advertisement

Missing Data Methods in HIV Clinical Trials: Regulatory Guidance And Alternative Approaches

  • 3 Citations

Abstract

Efficacy in HIV clinical trials is measured by changes in HIV RNA levels over time as well as the proportion of subjects with HIV RNA levels below an assay’s threshold of reliable quantification at a single time point. Missing data arise naturally due to missed visits and premature discontinuations of treatment. The available data are then analyzed using repeated measures models and univariate comparisons of proportions, assuming missing data occur at random or considering missing values as treatment failures (worst case scenario). These and other methods recently proposed by regulatory authorities are presented along with alternative approaches. Advantages and disadvantages of each method are discussed. Data from a recent comparison of ’ standard-of-care’ triple combination regimens are used for illustration.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 189

This is the net price. Taxes to be calculated in checkout.

References

  1. 1.

    Myers WR. Handling missing data in clinical trials: An overview. Drug Inf J. 2000;34:525–533.

  2. 2.

    Little RJA, Rubin DB. Statistical Analysis with Missing Data, New York, NY: Wiley; 1987.

  3. 3.

    Murray J. Guidance for Industry—Clinical Considerations for Accelerated and Traditional Approval for Antiviral Drugs Using Plasma Viral RNA Measurements. Rockville, MD: US Food and Drug Administration; 1999.

  4. 4.

    Committee for Proprietary Medicinal Products (CPMP). Points to consider in the Assessment of an Anti-HIV Medicinal Product. London, UK: The European Agency for the Evaluation of Medicinal Products; 2000.

  5. 5.

    Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963–974.

  6. 6.

    Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute Inc; 1996.

  7. 7.

    Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22.

  8. 8.

    Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: Wiley; 1987.

  9. 9.

    Rubin DB. Multiple imputation after 18+ years (with discussion). J Am Stat Assoc. 1996;91:473–489.

  10. 10.

    Schafer JL. Analysis of Incomplete Multivariate Data. New York, NY: Wiley; 1997.

Download references

Author information

Correspondence to Thomas Kelleher PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kelleher, T., Thiry, A., Wilber, R. et al. Missing Data Methods in HIV Clinical Trials: Regulatory Guidance And Alternative Approaches. Ther Innov Regul Sci 35, 1363–1371 (2001). https://doi.org/10.1177/009286150103500432

Download citation

Key Words

  • Missing data
  • HIV
  • Clinical trials
  • Regulatory guidance